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Abstract
Rationale: Adults may exhibit characteristics of both asthma and
chronic obstructive pulmonary disease (COPD), a situation recently
described as asthma–COPD overlap (ACO). There is a paucity of
information about ACO in primary care.
Objectives: To estimate the prevalence and describe characteristics of
individuals withACO in primary care practices among patients currently
diagnosed with asthma, COPD, or both; and to compare the prevalence
and characteristics of ACO among the three source populations.
Methods: The Respiratory Effectiveness Group conducted a cross-
sectional study of individuals >40 years old and with >2 outpatient
primary care visits over a 2-year period in theUKOptimumPatient Care
Research Database. Patients were classiﬁed into one of three source
populations based on diagnostic codes: 1) COPD only, 2) both asthma
and COPD, or 3) asthma only. ACOwas deﬁned as the presence of all of
the following 1) age >40 years, 2) current or former smoking, 3) post-
bronchodilator airﬂow limitation (forced expiratory volume in 1 second/
forced vital capacity ,0.7), and 4) >12% and >200 ml reversibility in
post-bronchodilator forced expiratory volume in 1 second.
Results: Among 2,165 individuals (1,015 COPD only, 395 with
both asthma and COPD, and 755 asthma only), the overall
prevalence of ACO was 20% (95% conﬁdence interval, 18–23%).
Patients with ACO had a mean age of 70 years (standard deviation,
11 yr), 60% were men, 73% were former smokers (the rest were
current smokers), and 66% were overweight or obese. Comorbid
conditions were common in patients with ACO, including diabetes
(53%), cardiovascular disease (36%), hypertension (30%), eczema
(23%), and rhinitis (21%). The prevalence of ACO was higher
in patients with a diagnosis of both asthma and COPD (32%)
compared with a diagnosis of COPD only (20%; P, 0.001)
or asthma only (14%; P, 0.001). Demographic and clinical
characteristics of ACO varied across these three source populations.
Conclusions: One in ﬁve individuals with a diagnosis of COPD,
asthma, or both asthma and COPD in primary care settings have
ACO based on the Respiratory Effectiveness Group ACO Working
group criteria. The prevalence and characteristics of patients with
ACO varies across the three source populations.
Keywords: asthma–COPD overlap; asthma; comorbidities;
COPD; primary care
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Asthma and chronic obstructive pulmonary
disease (COPD) are respiratory conditions
deﬁned by the presence of airﬂow limitation
that is typically variable in asthma and
persistent in COPD. In clinical practice, it has
long been recognized that some patients present
with characteristics consistent with both asthma
and COPD (1). Yet, there is limited evidence on
the optimal approach to evaluate and manage
this population, because they are typically
excluded from clinical trials (2, 3).
In 2014, the Global Initiative for
Asthma (GINA) and Global Initiative for
Chronic Obstructive Lung Disease (GOLD)
published a joint statement proposing the
term “asthma–COPD overlap syndrome”
(ACOS) to refer to individuals with features
of both conditions (4). GINA and GOLD
subsequently revised the term ACOS to
“asthma–COPD overlap” (ACO) to reduce
the likelihood that clinicians would regard
ACOS as a single entity or disease rather
that an umbrella term comprising many
phenotypes (5). Guidelines (e.g., from Spain,
Czech Republic, and Finland) have similarly
identiﬁed the need to acknowledge individuals
with features of both asthma and COPD and
the paucity of evidence to guide their care (6–8).
The GINA and GOLD joint statements
describe 11 clinical characteristics that may
be used to distinguish asthma from COPD
and identify patients with ACO (exhibiting a
similar number of asthma and COPD
features), including age, lung function, and
comorbid conditions (3–5). The joint
statement also acknowledges the paucity of
evidence to support these recommendations
and that further research is essential.
Various groups have subsequently used
different criteria for the diagnosis of ACO,
so not surprisingly have reported a wide
range of prevalences (z10–50%) (9–16).
Although most patients with asthma or
COPD receive health care in primary care
settings, there is limited information about
the prevalence and characteristics of
individuals with ACO in these settings. Also,
to our knowledge, no studies have compared
the prevalence and characteristic of
individuals with features suggestive of ACO
according to the source population (e.g.,
those currently diagnosed with asthma only
vs. COPD only vs. both diagnoses). The
Respiratory Effectiveness Group (REG)
ACO Working Group therefore conducted
a study that included two objectives: to
estimate the prevalence and describe
characteristics of individuals with ACO in
primary care practices among patients
currently diagnosed with asthma, COPD, or
both asthma and COPD; and to compare the
prevalence and characteristics of ACO
within the three source populations. To
increase the generalizability of our ﬁndings
to “real-world” patients in primary care
settings, the REG ACOWorking group used
clinical information documented in primary
care practices to deﬁne ACO. Results of the
current study are intended to support
the design of subsequent longitudinal
observational studies that will estimate the
clinical and economic burden of ACO in
primary care, and practice-based clinical
trials of different management strategies for
individuals with ACO in primary care.
Methods
REG ACO Working Group
This working group is a group of primary
care and specialist clinicians and researchers
from 14 countries with expertise in
comparative effectiveness research in
respiratory medicine (17–19).
Data Source and Ethics
The Optimum Patient Care Research
Database (OPCRD) contains anonymized
demographic, clinical, and physiological
data from primary care practices in the
United Kingdom. At the time of the study,
the OPCRD contained longitudinal medical
records from 576 practices. Clinical
diagnoses (including asthma, COPD, and
both) are recorded in the OPCRD as “Read
codes,” a dictionary of clinical codes
routinely used by general practitioners in
the UK National Health Service. Read code
lists are created for the OPCRD through
consensus by a panel of UK clinical
academics with expertise working in (and
coding) primary care respiratory medicine.
The Read code lists for the OPCRD are
routinely reviewed to ensure they remain up
to date and follow the model previously
validated for the Clinical Practice Research
Datalink, another large UK primary care
database (20). The OPCRD has been
approved for clinical research use by the
Health Research Authority of the UK
National Health System (REC reference
#15/EM/0150) (21).
The study was conducted in line
with the Strengthening the Reporting of
Observational Studies in Epidemiology
Statement for observational research and
included an a priori research plan, study
registration with commitment to publish,
and an independent steering committee not
remunerated for their participation (22).
The study protocol was developed by a
REG ACO Working Group, approved by
the OPCRD’s independent Anonymized
Ethics and Protocol Transparency
Review Committee (ADEPT1316), and
registered with the European Network of
Centres for Pharmacoepidemiology and
Pharmacovigilance (ENCePP; reference:
EUPAS13959). Written informed consent was
not necessary because of the deidentiﬁed nature
of the data and because patients are given the
option to prohibit use of their data for research.
Study Design
This was a cross-sectional study using
data from clinical encounters (visits)
documented in the OPCRD from January 1,
2014, through December 31, 2015.
Study Population
Patients were eligible if they had at least two
outpatient visits in primary care during the
2-year study period; no missing data for
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information used to identify individuals
with ACO (see DEFINITION OF ACO); were at
least 40 years old; and had a diagnosis
(i.e., had a Read code) of asthma, COPD, or
both asthma and COPD (see Figure E1 in the
online supplement). Patients were classiﬁed
into one of three source populations
according to the documentation in the
OPCRD: 1) COPD only: two visits with a
COPD diagnosis and no visits with a
diagnosis of asthma; 2) both asthma and
COPD: one visit with an asthma diagnosis
and one visit with a COPD diagnosis, or two
visits with diagnoses of both asthma and
COPD; or 3) asthma only: two visits with an
asthma diagnosis and no visits with a
diagnosis of COPD. In individuals with more
than two primary care outpatient visits over a
2-year period, we used the information
documented at the two most recent visits.
Deﬁnition of ACO
Various publications have used a range of
criteria for ACO, indicating the lack of
consensus on a deﬁnition for ACO (6–16).
Previous studies have deﬁned ACO as self-
reported asthma in individuals with post-
bronchodilator (post-BD) airﬂow limitation
(10), International Classiﬁcation of Diseases
codes for both asthma and COPD (14), and
a combination of criteria (e.g., post-BD
airﬂow limitation, a history of smoking at
least 10 pack-years or equivalent indoor or
outdoor air pollution, asthma diagnosis
before the age of 40 yr, and peripheral
blood eosinophilia) (16). To estimate the
prevalence of ACO that would be applicable
to a real-world primary care setting, rather
than in subspecialty care settings or using
data collected as part of cohort studies or
clinical trials, the REG ACO Working
Group elected to deﬁne ACO on the basis of
information documented by clinicians in
primary care. We did not rely on a clinician
diagnosis of both asthma and COPD to
deﬁne ACO. In this report, ACO is deﬁned
as the presence of all four of the following: 1)
age>40 years, 2) current or former smoking,
3) post-BD airﬂow limitation (forced
expiratory volume in 1 second [FEV1]/forced
vital capacity ,0.7), and 4) a post-BD
response (>12% and>200ml reversibility in
post-BD FEV1). Smoking history was based
on the question: “What best describes you?
A) Never smoked, B) Used to smoke, but
don’t now, C) Still smoking.” Individuals who
reported they were B or C were considered as
current or former smokers. Documentation
of pack-years smoked was inconsistent, so we
did not require a speciﬁc threshold of pack-
years smoked. Because we intended to
assess and compare the prevalence and
characteristics of ACO in three source
populations (diagnosis of asthma, COPD, or
both), we did not include these diagnoses as
criteria for ACO.
Demographic and Clinical
Characteristics
We queried the OPCRD to collect
information on age, sex, smoking history
(current, former, never), physician-recorded
comorbid diagnoses, height, and weight. We
calculated the body mass index (BMI) and
categorized individuals as underweight
(,18.5 kg/m2), normal (18.5–24.9 kg/m2),
overweight (25–29.9 kg/m2), or obese
(>30 kg/m2) (23).
Analyses
Descriptive statistics used means, standard
deviations, and proportions with 95%
conﬁdence intervalss. Student’s t tests and
chi-square tests, where appropriate, were
used to compare the prevalence of ACO and
their clinical characteristics across the three
source populations. A two-tailed P value
,0.05 deﬁned a signiﬁcant difference. We
did not adjust for multiple comparisons
across the different source populations,
because these were exploratory (rather than
conﬁrmatory) hypothesis tests.
Role of the Funding Source
This study was funded by the REG, an
international, investigator-led, not-for-proﬁt,
real-life respiratory research and advocacy
initiative (19). Optimum Patient Care
Limited donated OPCRD access. The authors
had full access to the data in the study, took
ﬁnal responsibility for the decision to submit
for publication, and did not receive honoraria
for preparing this report.
Results
Prevalence and Characteristics
of ACO in the Combined Study
Population
Of 233,054 healthcare encounters with two
or more primary care visits over a 2-year
period, information needed to apply the
REG ACO Working Group deﬁnition of
ACO was not available in 229,285 (98%)
visits (see online supplement). Of 3,433
individuals at least 40 years of age in whom
there was sufﬁcient information to apply the
ACO criteria, 1,015 (30%) had a diagnosis of
COPD only, 395 (11%) had diagnoses of
both asthma and COPD, 755 (22%) had a
diagnosis of asthma only, and 1,268 (37%)
did not have diagnosis of asthma or COPD.
Table 1. ACO prevalence in the source populations
Diagnosis of
COPD Only
(n=1,015)
Diagnosis of Both
Asthma and
COPD (n= 395)
Diagnosis of
Asthma Only
(n= 755)
All (n=2,165)
ACO prevalence 20.5% (208/1,015)
95% CI, 18.0–23.1%
32.1% (127/395)
95% CI, 27.6–37.0%
14.4% (109/755)
95% CI, 12.0–17.1%
20.5% (444/2,165)
95% CI, 18.8–22.2%
P value (vs. both asthma
and COPD)
P,0.001 Reference P,0.001 Not applicable
Definition of abbreviations: ACO=asthma–COPD overlap; CI = confidence interval; COPD=chronic obstructive pulmonary disease.
P values denote comparisons with ACO within individuals currently diagnosed as both asthma and COPD (Reference population).
Prevalence is defined as the proportion of individuals in each source population (diagnosis of COPD only, both asthma and COPD, and asthma only among
those who were at least 40 yr old) with documentation of all of the following: history of current or past smoking, post-bronchodilator airflow limitation, and
post-bronchodilator reversibility (see METHODS for details).
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In the 2,165 individuals with a diagnosis of
COPD, asthma, or both (three “source
populations”), 444 (20%; 95% conﬁdence
interval, 19–22%) met the REG ACO
Working Group criteria for ACO (Table 1).
Individuals with ACO had a mean age of 70
years, 60% were men, 73% were former
smokers, and 66% were overweight or obese.
Comorbid conditions were common in
patients with ACO; the ﬁve most common
comorbid conditions were diabetes (53%),
cardiovascular disease (36%), hypertension
(30%), eczema (23%), and rhinitis (21%)
(Table 2).
Prevalence and Characteristics of
ACO within Each Source Population
The prevalence of ACO in individuals with a
diagnosis of both asthma and COPD (32%)
was signiﬁcantly higher than in those with a
diagnosis of COPD only (20%) (Figures 1
and 2) or asthma only (14%) (Figure 3)
(P, 0.001 for each pair-wise comparison)
(Table 1). The lack of post-BD reversibility
was the most common reason that patients
with COPD only (53%; 542/1,015)
(Figure 1) or both asthma and COPD (30%;
117/395) (Figure 2) did not meet ACO
criteria. By contrast, the absence of a
smoking history was the most common
reason that patients with asthma only did
not meet criteria for ACO (43%; 326/755)
(Figure 3).
Sex and the prevalence of several
common (e.g., diabetes, cardiovascular
disease, hypertension, and eczema) and less
common (e.g., bronchiectasis, heart failure,
and cerebrovascular disease) comorbid
conditions were not signiﬁcantly different in
the individuals with ACO across the three
source populations (Table 2). Conversely,
individuals with ACO within the COPD-
only population were older (mean age, 72 vs.
68 yr; P= 0.04), more likely to be current
smoker (29 vs. 17%; P= 0.03), had a lower
BMI (e.g., 58 vs. 76% were overweight or
obese), were less likely to have rhinitis (17
vs. 33%; P, 0.01), and more likely to have
chronic kidney disease (14 vs. 6%; P= 0.04)
compared with those with ACO within the
asthma-only population.
There were fewer differences in clinical
characteristics when comparing individuals
with ACO within the group diagnosed as
both asthma and COPD compared with
those within the asthma-only or within the
COPD-only populations. Compared with
Table 2. Clinical characteristics of patients with ACO identiﬁed within each source population
Characteristics All ACO
(n= 444)
COPD
Only
(n= 208)
Both
Asthma
and COPD
(n=127)
Asthma
Only
(n= 109)
COPD Only
versus
AsthmaOnly,
P Value
COPD Only
versus Both
Asthma and
COPD,
P Value
Asthma Only
versus Both
Asthma and
COPD,
P Value
Age* yr, mean (SD) 70.0 (10.6) 72.0 (10.1) 68.4 (10.5) 68.1 (11.1) 0.04 0.04 0.73
Sex Male 264 (59.5) 131 (63.0) 71 (55.9) 62 (56.9) 0.30 0.20 0.80
Smoking history* Current smoker 118 (26.6) 60 (28.9) 39 (30.7) 19 (17.4) 0.03 0.72 0.02
Former smoker 326 (73.4) 148 (71.1) 88 (69.3) 90 (82.6)
BMI* Underweight 15 (3.4) 11 (5.3) 2 (1.6) 2 (1.8) 0.01 0.03 0.72
Normal weight 136 (30.6) 76 (36.5) 36 (28.4) 24 (22.0)
Overweight 160 (36.0) 73 (35.1) 44 (34.7) 43 (39.5)
Obese 133 (30.0) 48 (23.1) 45 (35.4) 40 (36.7)
Comorbidities Diabetes 236 (53.2) 112 (53.9) 64 (50.4) 50 (55.1) 0.84 0.54 0.47
Cardiovascular
disease
161 (36.3) 81 (38.9) 38 (29.9) 42 (38.5) 0.94 0.10 0.16
Hypertension 134 (30.2) 66 (31.7) 34 (26.8) 34 (31.2) 0.92 0.34 0.46
Eczema 101 (22.8) 50 (24.0) 24 (18.9) 27 (24.8) 0.90 0.27 0.27
Rhinitis* 95 (21.4) 36 (17.3) 23 (18.1) 36 (33.0) ,0.01 0.85 0.01
Ischemic heart
disease
91 (20.5) 48 (23.1) 23 (18.1) 20 (18.4) 0.33 0.28 0.96
Gastroesophageal
reﬂux
81 (18.2) 38 (18.3) 21 (16.5) 22 (20.2) 0.68 0.69 0.88
Chronic kidney
disease*
51 (11.5) 30 (14.4) 14 (11.0) 7 (6.4) 0.04 0.37 0.21
Osteoporosis 41 (9.2) 20 (9.6) 14 (11.0) 7 (6.4) 0.33 0.68 0.22
Anxiety or
depression
37 (8.3) 16 (7.7) 10 (7.9) 11 (10.1) 0.47 0.95 0.51
Myocardial
infarction
34 (7.7) 17 (8.2) 10 (7.9) 7 (6.4) 0.58 0.92 0.67
Cerebrovascular
disease
27 (6.1) 15 (7.2) 4 (3.2) 8 (7.3) 0.97 0.12 0.14
Heart failure 21 (4.7) 12 (5.6) 6 (4.7) 3 (2.8) 0.23 0.68 0.43
Bronchiectasis 18 (4.1) 10 (4.8) 6 (4.7) 2 (1.8) 0.20 0.97 0.22
Definition of abbreviations: ACO=asthma–COPD overlap; BMI=body mass index; COPD=chronic obstructive pulmonary disease; SD=standard deviation.
Comorbidities as recorded in clinical documentation.
Values represent n (%), unless otherwise indicated.
BMI categorized as underweight (,18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), or obese (>30 kg/m2).
*P,0.05 for each pairwise comparison.
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individuals with ACO within the COPD-
only source population, those with ACO
within the group with a diagnosis of both
asthma and COPD were younger (68 vs.
72 yr; P= 0.04) and had higher BMI (e.g., 70
vs. 58% were overweight or obese). By
contrast, compared with individuals with
ACO within the asthma-only source
population, those with ACO within the both
asthma and COPD population were more
likely a current smoker (31 vs. 17%; P= 0.02)
and less likely to have rhinitis (18 vs. 33%;
P= 0.01).
Discussion
In this cross-sectional study in primary care
practices, approximately one in ﬁve patients
with a current diagnosis of COPD, asthma,
or both conditions fulﬁlled the REG
Working Group deﬁnition for ACO.
Individuals with ACO were in the sixth
decade, were predominantly men, former
smokers, overweight or obese, and had
various comorbid conditions. The
prevalence of ACO varied according to the
source population. ACO prevalence was
highest among individuals with a current
diagnosis of both asthma and COPD, and
lowest in individuals with a diagnosis of
asthma only, chieﬂy because of absence
of smoking history. Demographic and
comorbid diagnoses among individuals
with ACO varied across the three source
populations.
There are limited data about
ACO in primary care. In an analysis
of the MAJORICA (Majorca Real-Life
Investigation in COPD and Asthma)
cohort, investigators used International
Classiﬁcation of Diseases-9 codes for both
asthma and COPD to deﬁne ACO and
reported a prevalence of ACO of 6 per 1,000
population, compared with 30 per 1,000
population for COPD only (14). Our study
contributes to the literature on ACO in
primary care by using an expanded
combination of patient-reported and lung
function criteria to deﬁne ACO (age>40 yr,
current or former smoking, post-BD airﬂow
limitation, and a post-BD response in FEV1)
and by comparing the prevalence of ACO
within three different source populations
(current diagnosis of COPD only, asthma
only, or both asthma and COPD). The
results indicate that about one in ﬁve
individuals diagnosed with COPD only and
about one in seven individuals diagnosed
with asthma only in primary care meet the
REG ACO Working Group criteria for
ACO. In a review of studies conducted in 19
different countries, the prevalence of ACO
varied from 11% to 61% of patients with a
diagnosis of asthma and 4% to 66% of
patients with a diagnosis of COPD (24). A
range of ACO deﬁnitions were used in these
various studies and likely contributed to
5- to 10-fold range in the estimates of ACO
prevalence.
The estimates of the prevalence of ACO
presented in our study are consistent with
these previous reports, but our report is
unique in presenting the prevalence ACO
using the same criteria in three different
source populations (patients with a
diagnosis of COPD only, patients with a
diagnosis of both asthma and COPD,
patients with a diagnosis of asthma only).
We are now planning to test the ACO
deﬁnition used in this report in other
populations, which will help us more
directly assess the generalizability of
ﬁndings. In addition, we found that only one
in three individuals currently diagnosed
with both asthma and COPD meet the REG
ACO Working Group criteria for ACO,
calling into question the basis on which this
combination of diagnoses is made in
primary care. More than 20% (86/395) of
patients with a current diagnosis of both
asthma and COPD in our report failed to
demonstrate post-BD airﬂow limitation,
suggesting a possible overdiagnosis of
COPD in patients with asthma, although
even in populations with asthma reversibility
is known to be variable between and within
individuals.
We also noted differences in some
demographic and clinical characteristics
(e.g., age, smoking history, BMI, and some
Diagnosis of COPD
N=1,015
Current or former smoker
N=940 (93%)
Airflow limitation
(Post-bronchodilator FEV1/FVC<0.7)
N=750 (74%)
Post-bronchodilator response in FEV1
(12% and 200mL increase in FEV1)
N=208 (20%)
Not current or former
smoker
N=75 (7%)
No airflow limitation
N=190 (19%)
No post-bronchodilator
response in FEV1
N=542 (53%)
Figure 1. Asthma–chronic obstructive pulmonary disease (COPD) overlap (ACO) in patients with a
current diagnosis of COPD only. Among individuals with a current diagnosis of COPD only, 208/1,015
(20.5%)met Respiratory Effectiveness Group ACOWorking Group criteria for ACO. Themost common
reason for notmeeting criteria for ACO is the lack of a post-bronchodilator response in forced expiratory
volume in 1 second (542/1,015; 53.3%). FEV1= forced expiratory volume in 1 second; FVC= forced
vital capacity.
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comorbid conditions) of individuals with
ACO across the three source populations.
Several phenotypic features found in
patients with ACO have been suggested to
inﬂuence prognosis. These include smoking
history, peripheral blood eosinophil counts,
patterns of airway inﬂammation, and age of
onset of asthma (25–27). Our observations
suggest that the source population from
which individuals with ACO are identiﬁed
may contribute to heterogeneity, in
estimates of prevalence, demographics,
clinical characteristics, and health outcomes.
Additional studies are needed to conﬁrm
this speculation.
Strengths of our study are the size of the
cohort (more than 2,000 patients), the use of
both clinical and lung function criteria to
deﬁne ACO, and the use of clinical data
from primary care practices. Use of routine
clinical data increased the likelihood of our
results being representative of primary care
populations.
The current study also has several
limitations. It included patients from a
single country (the United Kingdom). Also,
information needed to apply the REG ACO
Working Group deﬁnition of ACO
(smoking history, airﬂow limitation, and
post-BD response) was not available in
229,285 of 233,054 (98%) healthcare
encounters in individuals with two or more
primary care visits over a 2-year period.
These ﬁndings raise concerns about relying
on information recorded for clinical
purposes (as we did in our study), because it
could have led to selection bias. Deﬁning
ACO without spirometry results would have
reduced the number of people with missing
data, but would have raised concerns about
the validity of deﬁning ACO without
objective evidence of airﬂow limitation and
improvement in airﬂow limitation after use
of BDs. Also, we did not have information
about pack-years smoked, so may have
misclassiﬁed individuals with minimal (e.g.,
,1 pack-year) smoking history as having
ACO. Although these missing data
prevent us from considering the study
population as representative of all patients
with asthma, COPD, both diagnoses
in primary care, the low proportion of
patients with sufﬁcient data to apply REG
Working Group ACO criteria corresponds
to what is unfortunately observed in many
real-life primary care settings. Moreover, we
used evidence of a post-BD response in
FEV1 as one of the criteria for ACO. Studies
have shown that the post-BD response may
vary within an individual over a period
of 1 week to 2 months (28–30), and this
variability could have contributed to
misclassiﬁcation of individuals with ACO.
We considered including peripheral blood
eosinophilia as a criterion for ACO, but
were concerned that this information
may not be collected at the time of the
other criteria or may be affected by
concurrent treatment with systemic
corticosteroids.
Our ACO criteria were based on
convenience (information recorded in
health records during primary care
practice) and consensus of primary care
and specialist clinicians and researchers
from 14 countries with expertise in
comparative effectiveness research in
respiratory medicine, rather than data
related to the pathogenesis of airways
disease. As in previous studies of ACO, the
absence of a widely accepted consensus
deﬁnition of ACO is a limitation in the ﬁeld
(9–16). Until then, we are left with different
opinions when deﬁning ACO, similar to
the approaches currently used to deﬁne
acute respiratory distress syndrome or
sepsis (31, 32). Additional studies are
needed to compare the prevalence and
clinical characteristics (e.g., clinical
response to pharmacotherapy) of
individuals with ACO as deﬁned by the
REG Working Group criteria and alternate
ACO deﬁnitions. Such studies will help us
to identify deﬁnitions for ACO that have
a functional consequence. A further
limitation of our study is that we did
not have information about potential
contributory factors for airway disease,
such as indoor or outdoor air pollution,
which might have an effect similar to
smoking. We used spirometry results
Diagnosis of both asthma and COPD
N=395
Current or former smoker
N=330 (84%)
Airflow limitation
(Post-bronchodilator FEV1/FVC<0.7)
N=244 (62%)
Post-bronchodilator response in FEV1
(12% and 200mL increase in FEV1)
N=127 (32%)
Not current or former
smoker
N=65 (16%)
No airflow limitation
N=86 (22%)
No post-bronchodilator
response in FEV1
N=117 (30%)
Figure 2. Asthma–chronic obstructive pulmonary disease (COPD) overlap (ACO) in patients with a
current diagnosis of both asthma and COPD. Among individuals with a current diagnosis of both
asthma andCOPD, 127/395 (32.1%)met Respiratory EffectivenessGroup ACOWorkingGroup criteria
for ACO. Themost common reason for not meeting criteria for ACO is the lack of a post-bronchodilator
response in forced expiratory volume in 1 second (117/395; 29.6%). FEV1 = forced expiratory volume in
1 second; FVC= forced vital capacity.
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obtained as part of clinical practice, which
may have varied in quality and led to
misclassiﬁcation. Lastly, we used a cross-
sectional design. Cohort studies are needed
to assess the consequence of clinical and
physiologic characteristics (e.g., age at
diagnosis of asthma, change in BD response
in COPD, smoking patterns, and blood
eosinophil counts), and the consequence of
ACO among individuals identiﬁed within
different source populations.
In conclusion, we found that about
one in ﬁve patients with a clinical
diagnosis of asthma, COPD, or both
conditions in routine primary care
practices met REG ACO Working Group
criteria for ACO. The prevalence of ACO
in primary care was highest among
patients with a diagnosis of both asthma
and COPD (one in three), followed by
individuals with a diagnosis of COPD only
(one in ﬁve) and individuals with a
diagnosis of asthma only (one in seven).
The characteristics of patients with ACO,
including age, sex, smoking status,
BMI, and pattern of some comorbid
conditions, varied signiﬁcantly across the
different source populations, suggesting
ACO as deﬁned in our report likely
comprises a heterogeneous set of
subpopulations. Although use of
information recorded by clinicians in
primary care offered the opportunity for
our results to be more generalizable, our
study also highlights the disadvantage of
relying on clinical documentation (i.e.,
potential for missing data or variable
quality of information). Nevertheless, we
recommend use of the REG ACOWorking
Group deﬁnition in other patient populations
to estimate the prevalence of ACO, and
longitudinal studies using observational and
clinical trial designs to understand the
functional consequence in ACO patients in
primary care settings. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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